Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform

Novartis Pharmaceuticals

Summary

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Eligibility

Age range: 18–115 years
Sex: Male
Healthy volunteers: No

Detailed criteria

Inclusion criteria: * Diagnosis of mCRPC between 01 January 2021 and 31 December 2025. * Male sex at index, where index is the date of initial mCRPC diagnosis. * Age 18 years at index. Exclusion criteria: • None

Location

Novartis
East Hanover, New Jersey

Summary

Eligibility

Location

Conditions